Table 3 Vital signs after sedative administration
Variables | Pre-weighted analysis | Post-weighted analysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
All cohort (n = 149) | Chloral hydrate group (n = 75) | Dexmedetomidine group (n = 74) | Statistic | p Value | All cohort (n = 298) | Chloral hydrate group (n = 150) | Dexmedetomidine group (n = 148) | Statistic | p Value | |
Heart rate (bpm) | ||||||||||
Pre-administration | 126.9 ± 21.0 | 128.8 ± 20.8 | 125.0 ± 21.0 | 1.11 | 0.2697 | 126.6 ± 29.8 | 127.6 ± 29.7 | 125.5 ± 30.0 | 0.62 | 0.5370 |
Falling asleep | 105.3 ± 19.5 | 112.1 ± 17.4 | 98.9 ± 19.3 | 4.26 | < 0.001 | 105.0 ± 27.6 | 110.8 ± 25.5 | 99.6 ± 27.5 | 3.54 | < 0.001 |
Finishing TTE scan | 106.8 ± 24.6 | 114.2 ± 22.8 | 100.2 ± 24.5 | 3.4 | < 0.001 | 106.5 ± 34.6 | 112.7 ± 32.9 | 101.0 ± 34.5 | 2.83 | 0.005 |
Recovery at PACU | 121.2 ± 22.3 | 129.0 ± 21.5 | 114.3 ± 20.8 | 3.95 | < 0.001 | 120.8 ± 31.3 | 127.8 ± 30.7 | 114.6 ± 29.4 | 3.55 | < 0.001 |
SpO2 (%) | ||||||||||
Pre-administration | 93.6 ± 5.6 | 93.8 ± 4.9 | 93.4 ± 6.2 | 0.52 | 0.6052 | 93.6 ± 7.9 | 93.9 ± 7.0 | 93.4 ± 8.8 | 0.59 | 0.5544 |
Falling asleep | 94.2 ± 4.1 | 93.8 ± 4.7 | 94.5 ± 3.4 | − 1.03 | 0.3036 | 94.2 ± 5.8 | 93.9 ± 6.7 | 94.5 ± 4.8 | − 0.91 | 0.3620 |
Finishing TTE scan | 94.5 ± 4.4 | 94.4 ± 4.4 | 94.6 ± 4.4 | − 0.21 | 0.8378 | 94.5 ± 6.2 | 94.5 ± 6.1 | 94.6 ± 6.3 | − 0.08 | 0.9339 |
Recovery at PACU | 95.0 ± 4.1 | 94.7 ± 4.5 | 95.3 ± 3.7 | − 0.87 | 0.3879 | 95.0 ± 5.7 | 94.8 ± 6.3 | 95.3 ± 5.2 | − 0.70 | 0.4851 |